WILMINGTON, DE — AstraZeneca said new Phase III cancer and rare disease data presented at the American Society of Clinical Oncology annual meeting could strengthen the company’s position in several high-growth treatment markets, including liver cancer, breast cancer, and amyloidosis.
The pharmaceutical company outlined results and analyses spanning more than 85 research abstracts at the conference, including studies involving approved therapies and experimental medicines across oncology and rare diseases.
Among the most closely watched presentations was the Phase III EMERALD-3 trial, which evaluated the combination of IMFINZI (durvalumab) and IMJUDO (tremelimumab-actl), with or without lenvatinib, alongside transarterial chemoembolization in patients with unresectable liver cancer eligible for embolization procedures.
The company also presented new data from three major breast cancer programs targeting the leading metastatic breast cancer subtypes.
Results from the Phase III SERENA-6 study provided updated progression-free survival and circulating tumor DNA findings for camizestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer whose tumors developed ESR1 mutations.
Additional Phase III data came from the DESTINY-Breast09 trial evaluating ENHERTU in HER2-positive metastatic breast cancer and the TROPION-Breast02 study of DATROWAY in patients with metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitors.
Susan Galbraith, AstraZeneca’s executive vice president for oncology hematology research and development, said the breast cancer data reinforce the potential of ENHERTU, DATROWAY, and camizestrant while advancing the company’s strategy of moving newer therapies into earlier disease settings.
Beyond oncology, AstraZeneca highlighted Phase III results from the CARES clinical program evaluating anselamimab, an experimental treatment for light chain amyloidosis developed through its Alexion rare disease division.
The company said the study demonstrated clinically meaningful benefits for patients with kappa light chain amyloidosis, a rare disorder caused by abnormal protein deposits that can damage organs.
Gianluca Pirozzi, head of development, regulatory and safety at Alexion, said the findings suggest anselamimab’s mechanism of targeting amyloid deposits could help extend survival and reduce cardiovascular hospitalizations.
AstraZeneca also reported updated data from several earlier-stage development programs, including the antibody-drug conjugate puxitatug samrotecan for ovarian and endometrial cancers, the PRMT5 inhibitor AZD3470 for Hodgkin lymphoma, and NT-175, a T-cell receptor therapy being studied in advanced solid tumors.
The presentations come as AstraZeneca continues expanding its oncology portfolio through both internal development and partnerships. The company collaborates with Daiichi Sankyo on the development and commercialization of ENHERTU and DATROWAY.
The ASCO meeting was held from May 29 through June 2 in Chicago and is among the largest annual gatherings of cancer researchers, physicians, and drug developers.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.